Notably, in cases where YAP/TAZ upregulation drives drug resistance, increased YAP/TAZ activation is almost always coincident with changes in cell shape and actin reorganisation.22,24,28,39–42 Moreover, we recently demonstrated that in breast cancer cells, YAP/TAZ translocation rates are regulated by signalling pathways such as RAS/MAPK, ensuring that nuclear YAP/TAZ levels remain robust to changes in cell size.1 Since dysregulation of RAS/MAPK signalling is a common event in cancer, it could affect the relationship between YAP/TAZ and shape and size. The gene discussed is YAP1; the disease is breast carcinoma.